Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28351674 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL4026767 | 0.98 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL4180063 | 0.94 | CTSK (0.43) | ALDH1A1SMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL3799622 | 0.90 | PLA2G10 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL3470166 | 0.90 | PLA2G10 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL27147241 | 0.90 | PLA2G10 (0.41) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL15199218 | 0.87 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL10316747 | 0.85 | CTSK (0.38) | ALDH1A1SMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL4774700 | 0.85 | ALOX15 (0.41) | ALDH1A1SMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL14312161 | 0.84 | SIGMAR1 (0.48) | ALDH1A1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20240374738-A1 | BIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING RECEPTOR TYROSINE KINASE AND APPLICATION THEREOF | Taibidi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2024-11-14 | — | — | US | disclosed |
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2021-06-15 | — | — | US | disclosed |
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | HETERO LABS LIMITED (IN) | 2021-06-15 | — | — | US | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-112279848-A | Pan-JAKs inhibitor and application thereof | 四川海思科制药有限公司 | 2021-01-29 | — | — | CN | disclosed |
| WO-2020154447-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009093009-A1 | FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093013-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| EP-2076512-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009071476-A1 | ISOXAZOLO-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
| EP-2054417-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB Pharma S.A. (BE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008044022-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008020206-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | WO | disclosed |
| CN-1222153-A | Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders | GLAXO GROUP LTD (GB) | 1999-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | ALDH1A1 938/4885SMN1; SMN2 3318/4885GAA 2181/4885 |
| US-11034718-B2 | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | IL17A, CDK17, CCR3 | ALDH1A1 4020/4885SMN1; SMN2 4791/4885GAA 2831/4885 |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | ALDH1A1 3718/4885SMN1; SMN2 3642/4885GAA 4409/4885 |
| US-20240374738-A1 | BIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING RECEPTOR TYROSINE KINASE AND APPLICATION THEREOF | DDR1, DDR2, DDRGK1 | ALDH1A1 4192/4885SMN1; SMN2 1595/4885GAA 3723/4885 |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | ALDH1A1 192/4885SMN1; SMN2 4132/4885GAA 3070/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | ALDH1A1 4385/4885SMN1; SMN2 2485/4885GAA 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.